Search Results

Broadcast across the United States brings attention to the under-addressed risk of medication degradation caused by heat exposure and the real-world need for better medication protection and tracking

Windgap Medical, Inc., a leading specialty pharmaceutical and drug delivery platform company, announced that it has successfully completed its final close with over $39 million of Series B-1 equity financing, led by Taiwania Capital.

• Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2 approval decisions expected by year-end 2026 • Upcoming FDA Pre-BLA meeting will focus on the use of recent seroconversion biomarker data as a key surrogate clinical efficacy endpoint to support a BLA for OST-HER2 under the Accelerated Approval Program • Commercialization and reimbursement preparations well underway for the U.S., U.K., and Europe in parallel with ongoing partnership discussions